M. Frueh

471 total citations
31 papers, 322 citations indexed

About

M. Frueh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hepatology. According to data from OpenAlex, M. Frueh has authored 31 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 5 papers in Hepatology. Recurrent topics in M. Frueh's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). M. Frueh is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). M. Frueh collaborates with scholars based in Switzerland, United States and Canada. M. Frueh's co-authors include Daniel Betticher, Viviane Hess, Attila Kollár, Piercarlo Saletti, Roger von Moos, Sandro Anchisi, Peter Moosmann, Richard Herrmann, Markus Borner and Markus Joerger and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

M. Frueh

28 papers receiving 315 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Frueh Switzerland 9 258 189 43 41 40 31 322
B.C. Cho South Korea 8 204 0.8× 232 1.2× 47 1.1× 90 2.2× 15 0.4× 33 280
Javier Rodríguez Spain 11 247 1.0× 185 1.0× 34 0.8× 40 1.0× 22 0.6× 20 351
Ludovic Doucet France 10 172 0.7× 185 1.0× 71 1.7× 83 2.0× 18 0.5× 37 323
Patrick Texereau France 8 221 0.9× 93 0.5× 40 0.9× 25 0.6× 81 2.0× 15 280
M. Karina Greece 8 180 0.7× 119 0.6× 40 0.9× 21 0.5× 19 0.5× 12 277
T-E. Ciuleanu Romania 11 266 1.0× 240 1.3× 46 1.1× 57 1.4× 12 0.3× 47 345
Olçun Ümit Ünal Türkiye 10 132 0.5× 98 0.5× 54 1.3× 52 1.3× 20 0.5× 40 235
Susie Bae Australia 10 189 0.7× 135 0.7× 54 1.3× 28 0.7× 10 0.3× 32 274
A Masotti Italy 8 314 1.2× 339 1.8× 33 0.8× 64 1.6× 19 0.5× 13 399
Jean Philippe Metges France 8 224 0.9× 124 0.7× 76 1.8× 110 2.7× 23 0.6× 23 343

Countries citing papers authored by M. Frueh

Since Specialization
Citations

This map shows the geographic impact of M. Frueh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Frueh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Frueh more than expected).

Fields of papers citing papers by M. Frueh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Frueh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Frueh. The network helps show where M. Frueh may publish in the future.

Co-authorship network of co-authors of M. Frueh

This figure shows the co-authorship network connecting the top 25 collaborators of M. Frueh. A scholar is included among the top collaborators of M. Frueh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Frueh. M. Frueh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Curioni‐Fontecedro, Alessandra, M. Frueh, David König, et al.. (2023). 1412P SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors. Annals of Oncology. 34. S807–S808. 1 indexed citations
3.
Flatz, Lukas, M. Frueh, Stefan Diem, et al.. (2023). 1016O Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC. Annals of Oncology. 34. S619–S619.
4.
Schmid, Sabine, M. Frueh, Sacha I. Rothschild, et al.. (2023). 2191P Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting. Annals of Oncology. 34. S1133–S1134. 1 indexed citations
5.
Brown, M. Catherine, Frances A. Shepherd, Natasha B. Leighl, et al.. (2023). 2201P Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies. Annals of Oncology. 34. S1137–S1137.
6.
Klümper, Niklas, Fiamma Berner, Annkristin Heine, et al.. (2022). C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 10(3). e004024–e004024. 53 indexed citations
7.
8.
Zellweger, Núria, Sabine Schmid, Christine Waibel, et al.. (2022). 1540P Real-world analysis of outcomes of first-line chemo-immunotherapy in patients with extensive disease small cell lung cancer (ED-SCLC). Annals of Oncology. 33. S1251–S1251. 3 indexed citations
9.
Addeo, Alfredo, Markus Joerger, Sacha I. Rothschild, et al.. (2021). Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.. Journal of Clinical Oncology. 39(15_suppl). e21119–e21119. 4 indexed citations
10.
Rothschild, Sacha I., Alfred Zippelius, E.I. Eboulet, et al.. (2020). SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.. Journal of Clinical Oncology. 38(15_suppl). 9016–9016. 24 indexed citations
11.
Curioni‐Fontecedro, Alessandra, Jean Yannis Perentes, Hans Gelpke, et al.. (2019). Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08). British Journal of Cancer. 120(10). 968–974. 5 indexed citations
12.
Rothschild, Sacha I., Laetitia Mauti, Sabine Schmid, et al.. (2019). Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies. Annals of Oncology. 30. ii58–ii58. 9 indexed citations
13.
Metaxas, Yannis, M. Frueh, E.I. Eboulet, et al.. (2019). SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial. Annals of Oncology. 30. v748–v748. 2 indexed citations
14.
Drilon, Alexander, Laurent Mhanna, Julie Milia, et al.. (2018). Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).. Journal of Clinical Oncology. 36(15_suppl). 9010–9010. 37 indexed citations
15.
16.
Koeberle, Dieter, Daniel Betticher, Roger von Moos, et al.. (2013). Bevacizumab Continuation Versus No Continuation After First-Line Chemo-Bevacizumab Therapy in Patients with Metastatic Colorectal Cancer: a Phase 3 Non-Inferiority Trial. Annals of Oncology. 24. iv22–iv22. 1 indexed citations
17.
Koeberle, Dieter, Daniel Betticher, Roger von Moos, et al.. (2013). Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority trial (SAKK 41/06).. Journal of Clinical Oncology. 31(15_suppl). 3503–3503. 20 indexed citations
18.
19.
Baty, Florent, M. Frueh, S. Crowe, et al.. (2011). Whole blood transcriptomics analysis of 24h responses to bevacizumab/erlotinib in nonsquamous non-small cell lung cancer: A multicenter phase II trial SAKK19/05.. Journal of Clinical Oncology. 29(15_suppl). e21069–e21069. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B.C. Cho Breakdown of academic impact, for papers by Javier Rodríguez Breakdown of academic impact, for papers by Ludovic Doucet Breakdown of academic impact, for papers by Patrick Texereau Breakdown of academic impact, for papers by M. Karina Breakdown of academic impact, for papers by T-E. Ciuleanu Breakdown of academic impact, for papers by Olçun Ümit Ünal Breakdown of academic impact, for papers by Susie Bae Breakdown of academic impact, for papers by A Masotti Breakdown of academic impact, for papers by Jean Philippe Metges
Rankless by CCL
2026